Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Lung Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 1 · 33.3%

Non‐platinum therapies vs platinum combination

Overall survival · non‐small cell lung cancer in the elderly population

Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.76
13 studies · 13 participants
Moderate

Carboplatin vs cisplatin chemotherapy

Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer

Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).

1 finding from 1 review

Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
HR 0.99 [0.82, 1.2]
10 studies · 2515 participants
High

Non‐platinum single‐agent vs non‐platinum combination treatment

Overall survival (OS) · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.92
5 studies · 1294 participants
Low